What common targeted therapies does cabozantinib interact with?

Cabozantinib and abiraterone are two different drugs, each effective in treating different conditions. Determining which one is better is not a simple matter because it depends on many factors, including the patient's condition, the indications for the drug, and the individual's response.

Cabozantinib is a multi-target tyrosine kinase inhibitor that can simultaneously inhibit multiple targets related to tumor growth, angiogenesis and metastasis, such as MET, VEGFR, etc. This multi-target inhibitory property allows cabozantinib to demonstrate good clinical effects in a variety of cancers, including rectal cancer.

In clinical trials in patients with refractory metastatic colorectal cancer, cabozantinib demonstrated stable disease control. For example, in a phase II clinical trial, 45% of patients achieved a progression-free survival of 12 weeks. These data demonstrate the effectiveness of cabozantinib in the treatment of rectal cancer.

Abiraterone (Abiraterone) is a CYP17 inhibitor. It is clinically suitable for use in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer who have previously received docetaxel-containing chemotherapy. It has strong specificity and is mainly targeted at the treatment of prostate cancer.

Abiraterone has achieved remarkable results in the treatment of metastatic castration-resistant prostate cancer. Combined with prednisone, it can prolong patient survival and improve quality of life. However, there are no clear data supporting the efficacy of treatment for rectal cancer.

Cabozantinib is used in a variety of cancers, including rectal cancer, while abiraterone is mainly used in the treatment of prostate cancer. Cabozantinib has shown significant effectiveness in clinical trials for rectal cancer; while abiraterone has shown significant efficacy in the treatment of prostate cancer, but its efficacy in the treatment of rectal cancer is unknown.